PIK3CA and acute lymphoblastic leukemia: Based on this metabolic singularity, we proposed a novel treatment combining an asparagine and glutamine degrader with a PI3K signaling inhibitor that presents promising efficacy in T-ALL/LL harboring PI3K deregulation.